Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice

Jason O'connor, M. A. Lawson, C. André, M. Moreau, J. Lestage, N. Castanon, K. W. Kelley, R. Dantzer

Research output: Contribution to journalArticle

624 Citations (Scopus)

Abstract

Although elevated activity of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) has been proposed to mediate comorbid depression in inflammatory disorders, its causative role has never been tested. We report that peripheral administration of lipopolysaccharide (LPS) activates IDO and culminates in a distinct depressive-like behavioral syndrome, measured by increased duration of immobility in both the forced-swim and tail suspension tests. Blockade of IDO activation either indirectly with the anti-inflammatory tetracycline derivative minocycline, that attenuates LPS-induced expression of proinflammatory cytokines, or directly with the IDO antagonist 1-methyltryptophan (1-MT), prevents development of depressive-like behavior. Both minocycline and 1-MT normalize the kynurenine tryptophan ratio in the plasma and brain of LPS-treated mice without changing the LPS-induced increase in turnover of brain serotonin. Administration of L-kynurenine, a metabolite of tryptophan that is generated by IDO, to naive mice dose dependently induces depressive-like behavior. These results implicate IDO as a critical molecular mediator of inflammation-induced depressive-like behavior, probably through the catabolism of tryptophan along the kynurenine pathway.

Original languageEnglish (US)
Pages (from-to)511-522
Number of pages12
JournalMolecular Psychiatry
Volume14
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Lipopolysaccharides
Kynurenine
Tryptophan
Minocycline
Hindlimb Suspension
Inflammation Mediators
Brain
Tetracycline
Serotonin
Anti-Inflammatory Agents
Depression
Cytokines
Enzymes

Keywords

  • 1-methyltryptophan
  • Forced-swim test
  • Kynurenine
  • Minocycline
  • Tail suspension test
  • Tryptophan

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. / O'connor, Jason; Lawson, M. A.; André, C.; Moreau, M.; Lestage, J.; Castanon, N.; Kelley, K. W.; Dantzer, R.

In: Molecular Psychiatry, Vol. 14, No. 5, 05.2009, p. 511-522.

Research output: Contribution to journalArticle

O'connor, J, Lawson, MA, André, C, Moreau, M, Lestage, J, Castanon, N, Kelley, KW & Dantzer, R 2009, 'Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice', Molecular Psychiatry, vol. 14, no. 5, pp. 511-522. https://doi.org/10.1038/sj.mp.4002148
O'connor, Jason ; Lawson, M. A. ; André, C. ; Moreau, M. ; Lestage, J. ; Castanon, N. ; Kelley, K. W. ; Dantzer, R. / Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. In: Molecular Psychiatry. 2009 ; Vol. 14, No. 5. pp. 511-522.
@article{a5500f1f46db4b08aeec27851c691c61,
title = "Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice",
abstract = "Although elevated activity of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) has been proposed to mediate comorbid depression in inflammatory disorders, its causative role has never been tested. We report that peripheral administration of lipopolysaccharide (LPS) activates IDO and culminates in a distinct depressive-like behavioral syndrome, measured by increased duration of immobility in both the forced-swim and tail suspension tests. Blockade of IDO activation either indirectly with the anti-inflammatory tetracycline derivative minocycline, that attenuates LPS-induced expression of proinflammatory cytokines, or directly with the IDO antagonist 1-methyltryptophan (1-MT), prevents development of depressive-like behavior. Both minocycline and 1-MT normalize the kynurenine tryptophan ratio in the plasma and brain of LPS-treated mice without changing the LPS-induced increase in turnover of brain serotonin. Administration of L-kynurenine, a metabolite of tryptophan that is generated by IDO, to naive mice dose dependently induces depressive-like behavior. These results implicate IDO as a critical molecular mediator of inflammation-induced depressive-like behavior, probably through the catabolism of tryptophan along the kynurenine pathway.",
keywords = "1-methyltryptophan, Forced-swim test, Kynurenine, Minocycline, Tail suspension test, Tryptophan",
author = "Jason O'connor and Lawson, {M. A.} and C. Andr{\'e} and M. Moreau and J. Lestage and N. Castanon and Kelley, {K. W.} and R. Dantzer",
year = "2009",
month = "5",
doi = "10.1038/sj.mp.4002148",
language = "English (US)",
volume = "14",
pages = "511--522",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice

AU - O'connor, Jason

AU - Lawson, M. A.

AU - André, C.

AU - Moreau, M.

AU - Lestage, J.

AU - Castanon, N.

AU - Kelley, K. W.

AU - Dantzer, R.

PY - 2009/5

Y1 - 2009/5

N2 - Although elevated activity of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) has been proposed to mediate comorbid depression in inflammatory disorders, its causative role has never been tested. We report that peripheral administration of lipopolysaccharide (LPS) activates IDO and culminates in a distinct depressive-like behavioral syndrome, measured by increased duration of immobility in both the forced-swim and tail suspension tests. Blockade of IDO activation either indirectly with the anti-inflammatory tetracycline derivative minocycline, that attenuates LPS-induced expression of proinflammatory cytokines, or directly with the IDO antagonist 1-methyltryptophan (1-MT), prevents development of depressive-like behavior. Both minocycline and 1-MT normalize the kynurenine tryptophan ratio in the plasma and brain of LPS-treated mice without changing the LPS-induced increase in turnover of brain serotonin. Administration of L-kynurenine, a metabolite of tryptophan that is generated by IDO, to naive mice dose dependently induces depressive-like behavior. These results implicate IDO as a critical molecular mediator of inflammation-induced depressive-like behavior, probably through the catabolism of tryptophan along the kynurenine pathway.

AB - Although elevated activity of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) has been proposed to mediate comorbid depression in inflammatory disorders, its causative role has never been tested. We report that peripheral administration of lipopolysaccharide (LPS) activates IDO and culminates in a distinct depressive-like behavioral syndrome, measured by increased duration of immobility in both the forced-swim and tail suspension tests. Blockade of IDO activation either indirectly with the anti-inflammatory tetracycline derivative minocycline, that attenuates LPS-induced expression of proinflammatory cytokines, or directly with the IDO antagonist 1-methyltryptophan (1-MT), prevents development of depressive-like behavior. Both minocycline and 1-MT normalize the kynurenine tryptophan ratio in the plasma and brain of LPS-treated mice without changing the LPS-induced increase in turnover of brain serotonin. Administration of L-kynurenine, a metabolite of tryptophan that is generated by IDO, to naive mice dose dependently induces depressive-like behavior. These results implicate IDO as a critical molecular mediator of inflammation-induced depressive-like behavior, probably through the catabolism of tryptophan along the kynurenine pathway.

KW - 1-methyltryptophan

KW - Forced-swim test

KW - Kynurenine

KW - Minocycline

KW - Tail suspension test

KW - Tryptophan

UR - http://www.scopus.com/inward/record.url?scp=65349135346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349135346&partnerID=8YFLogxK

U2 - 10.1038/sj.mp.4002148

DO - 10.1038/sj.mp.4002148

M3 - Article

C2 - 18195714

AN - SCOPUS:65349135346

VL - 14

SP - 511

EP - 522

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 5

ER -